Biomarker Discovery and Validation
Traditional “Omics” approaches to biomarker validation have significant constraints.
Traditional “Omics” approaches to biomarker validation have significant constraints.
Traditional “Omics” approaches to biomarker validation have significant constraints.
Genomics is not dynamic. Does not measure life.
Genomics is not dynamic. Does not measure life.
Transcriptomics is limited in depth and limited to gene expression. It misses changes that happen to proteins.
Transcriptomics is limited in depth and limited to gene expression. It misses changes that happen to proteins.
Limited in depth and difficulty to quantify. Costly and time consuming.
Limited in depth and difficulty to quantify. Costly and time consuming.
Other novel proteomics platforms translate the relative abundance of proteins in a sample to DNA sequences. This translation of information enables more reliable and cost-effective results by reading the information with next generation sequencing or qPCR analysis
These platforms still contain implicit constraints:
Other novel proteomics platforms translate the relative abundance of proteins in a sample to DNA sequences. This translation of information enables more reliable and cost-effective results by reading the information with next generation sequencing or qPCR analysis
These platforms still contain implicit constraints:
Aptamarkers can bind canonical proteins in their native state in plasma or tissue.
Aptamarkers can bind to protein complexes, protein misfoldings, isoforms, cleave events, ion-loadings, complexed with drugs, post-translation modifications and protein fragments.
Aptamarkers can bind to extra-cellular vesicles, metabolites and non-coding RNA
Aptamarkers allows end-users access to the oligo probes for diagnostic development.
Aptamarkers can bind canonical proteins in their native state in plasma or tissue.
Aptamarkers can bind to protein complexes, protein misfoldings, isoforms, cleave events, ion-loadings, complexed with drugs, post-translation modifications and protein fragments.
Aptamarkers can bind to extra-cellular vesicles, metabolites and non-coding RNA
Aptamarkers allows end-users access to the oligo probes for diagnostic development.
FRELEX is our patented system for selecting aptamers that bind to target molecules in their free state. This process enables partitioning of bound aptamers from unbound without a need to immobilize targets. FRELEX enables the selection of Aptamarkers for proteins in their native state in plasma or in tissue, including in complexes (dimers, trimers, etc), foldings, ion-loadings, complexed with drugs, and protein fragments.
FRELEX is our patented system for selecting aptamers that bind to target molecules in their free state. This process enables partitioning of bound aptamers from unbound without a need to immobilize targets. FRELEX enables the selection of Aptamarkers for proteins in their native state in plasma or in tissue, including in complexes (dimers, trimers, etc), foldings, ion-loadings, complexed with drugs, and protein fragments.
We have developed the NEOMER selection method for aptamer discovery. We have designed a closed system with a defined set of sequences in our library with higher structural diversity that found in a SELEX library. This enables the selection of the same set of sequences on different targets and reduces the selection rounds to a single step.
The neomer approach to Aptamarkers improves on existing next generation proteomics platforms by;
We have developed the NEOMER selection method for aptamer discovery. We have designed a closed system with a defined set of sequences in our library with higher structural diversity that found in a SELEX library. This enables the selection of the same set of sequences on different targets and reduces the selection rounds to a single step.
The neomer approach to Aptamarkers improves on existing next generation proteomics platforms by;
The Aptamarker platform is available exclusively through NeoVentures Biotechnology Europe
The Aptamarker platform is available exclusively through NeoVentures Biotechnology Europe
Applications to your specific projects, incorporation of approach in grant proposals or additional use cases.
Applications to your specific projects, incorporation of approach in grant proposals or additional use cases.
This conference took place on April 4th at Aptamers 2022.
Dr. Gregory Penner introduced our game-changing new method of aptamer selection. Hear what he has to say about it by watching the full presentation.
Fill in the form for instant access.
This conference took place on April 4th at Aptamers 2022.
Dr. Gregory Penner introduced our game-changing new method of aptamer selection. Hear what he has to say about it by watching the full presentation.
Fill in the form for instant access.